2007
DOI: 10.1186/1465-9921-8-37
|View full text |Cite
|
Sign up to set email alerts
|

Antisense oligonucleotide inhibition of Heat Shock Protein (HSP) 47 improves bleomycin-induced pulmonary fibrosis in rats

Abstract: Background: The most common pathologic form of pulmonary fibrosis arises from excessive deposition of extracellular matrix proteins such as collagen. The 47 kDa heat shock protein 47 (HSP47) is a collagen-specific molecular chaperone that has been shown to play a major role during the processing and/or secretion of procollagen.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

3
22
0

Year Published

2007
2007
2019
2019

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 34 publications
(25 citation statements)
references
References 29 publications
(25 reference statements)
3
22
0
Order By: Relevance
“…Therefore, TNF‐α has served as a candidate target for IPF treatment. Although systemic administration of anti‐TNF‐α Ab or soluble receptor in an animal model and an IPF patient resulted in sustained improvement , subcutaneous administration of etanercept did not bring about significant differences in the predefined endpoints among IPF patients who received etanercept or placebo . There were also studies that determined the risks of complications associated with the systemic immunosuppressive effects of systemic anti‐TNF‐α protein drug treatment, including granulomatous infections, bacterial infections, granulomatous disease, pulmonary nodules, interstitial pneumonitis, methotrexate pneumonitis and autoimmune disease .…”
Section: Discussionmentioning
confidence: 99%
“…Therefore, TNF‐α has served as a candidate target for IPF treatment. Although systemic administration of anti‐TNF‐α Ab or soluble receptor in an animal model and an IPF patient resulted in sustained improvement , subcutaneous administration of etanercept did not bring about significant differences in the predefined endpoints among IPF patients who received etanercept or placebo . There were also studies that determined the risks of complications associated with the systemic immunosuppressive effects of systemic anti‐TNF‐α protein drug treatment, including granulomatous infections, bacterial infections, granulomatous disease, pulmonary nodules, interstitial pneumonitis, methotrexate pneumonitis and autoimmune disease .…”
Section: Discussionmentioning
confidence: 99%
“…This abnormal process of fibrosis is responsible for the pulmonary dysfunction associated with IPF. Supporting this idea, genetic inhibition of neutrophil elastase, of the TGF-␤1-dependent signal transduction pathway, or of collagen synthesis was reported to suppress the progress of bleomycin-induced pulmonary fibrosis (5,9,14,52). However, it is not clear whether pharmacological inhibition of these factors can improve the prognosis for IPF in humans.…”
mentioning
confidence: 90%
“…Several therapeutic approaches have been used in order to suppress HSP47 signalling. Among them, antisense oligodeoxynucleotides (ODN) have been widely used for the suppression of the HSP47 gene in various animal models, such as wound healing, peritoneal fibrosis, pulmonary fibrosis, and anti-Thy-1.1-induced glomerulonephritis [30,31,32,33,34]; however, antisense ODN as a therapeutic tool has limitations, such as a short half-life and nonspecific activity. Recently, instead of ODN, RNA interference mediated by small interfering RNA (siRNA) was introduced as a powerful tool for silencing the gene expression [35,36,37,38].…”
Section: Introductionmentioning
confidence: 99%